In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guided Therapy Systems Keeps Options Open On Tissue Regen Device

Executive Summary

Guided Therapy Systems CEO Michael Slayton, PhD, has a history of breaking innovative medical technology, with a primary focus on diagnostic and therapeutic ultrasound applications. He tells In Vivo about the 22-year engineering journey that has led him and the company he founded to the cusp of market launch of a non-invasive tissue regeneration device for musculoskeletal injuries.

You may also be interested in...



Going More Than Skin Deep Into Merz’s Ulthera Acquisition

New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.

UK Medtech Strategy Before 2022 Year End, Government Promises

The UK government’s new procurement-and-beyond body housed in the DHSC says a medtech strategy could hit the presses before 2023. The medtech industry is cheered by promises of engagement.

Mike Mussallem: Inspiring People Is A Way Of Life

Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV004535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel